Investigation of the biology of insulin-like growth factor 1 and its derivatives for the development of new therapeutics. This project will investigate the biology of insulin-like growth factor 1, a key molecule in growth, development and, in particular, the wound healing process. Its success will lead to improved treatments for non-healing (chronic) wounds and, potentially, new anti-cancer treatments.
Proteomic study of urine to discover novel biomarkers for human prostate cancer. The purpose of this project is to identify novel markers in the urine of patients with prostate cancer. These biomarkers may ultimately prove useful in the development of novel diagnostic tools for the management of this disease.
Proteomic study of tears to discover novel biomarkers for human breast cancer. The purpose of this project is to identify novel markers in the tears of patients with breast cancer. The results from this study may improve the prognosis of breast cancer patients.
Unified platform for real time QA in radiation therapy in brachytherapy based on high resolution silicon detectors (Magic Plate). This project will design and manufacture new devices for measuring the amount of radiation given to the patient during radiotherapy. This will improve the accuracy and safety of cancer treatment as well as greatly reducing the time needed to perform essential safety checks.
DNA end resection: from basic mechanisms to genome editing. The project aims to understand processes underlying genome editing, a bioengineering process that introduces specific mutations into genomic DNA. Homologous recombination and nonhomologous end-joining pathways play a crucial role in repairing broken DNA strands, which are a toxic form of DNA damage. The proteins that function in the repair process have been recently identified, but it remains unclear how they function on a mechanistic l ....DNA end resection: from basic mechanisms to genome editing. The project aims to understand processes underlying genome editing, a bioengineering process that introduces specific mutations into genomic DNA. Homologous recombination and nonhomologous end-joining pathways play a crucial role in repairing broken DNA strands, which are a toxic form of DNA damage. The proteins that function in the repair process have been recently identified, but it remains unclear how they function on a mechanistic level and how either of the two main pathways is selected. The project aims to define how the activity of a key control protein, Sae2 (Sporulation in the Absence of Spo Eleven), is regulated by posttranslational modifications, and how this activates homologous recombination. The project plans to first use Saccharomyces cerevisiae yeast as a model and then to extend research into the human system in an attempt to improve the efficiency of genome editing. Read moreRead less
Rapid detection of rare-event cells by strong UP-conversion
encoded nano-radiators (SUPER Dots): finding a needle in a haystack. Current diagnostic tests are not sensitive enough to detect cancer in its very early stages or early recurrence following treatment. The new technologies developed by this project will be able to find single cancer cells in blood and urine samples heralding a new era in medical diagnostics.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100006
Funder
Australian Research Council
Funding Amount
$600,000.00
Summary
An adaptable and dedicated linear accelerator for medical radiation research. Leading radiation scientists developing innovative methods and devices for treating cancer patients will collaborate in future research using this highly adaptable linear accelerator for medical radiation research. Innovations in tumour targeting, better patient safety, new medical devices and improved cancer outcomes are expected.
Imaging Mass Spectrometry (IMS), a peptide biomarker discovery tool using tissue. Cancer is the second most common cause of death in Australia. The newly developed technology of Imaging Mass Spectrometry for peptides in tissue has the potential to discover biomarkers for early diagnosis of cancer. This new technology could avoid a number of cancer deaths and reduce suffering of patients through earlier and better diagnosis.
Characterisation of p14ARF intracellular trafficking pathways. Over 3500 new cases of melanoma are diagnosed in NSW each year, and one of the most important proteins involved in suppressing melanoma initiation or growth is p14ARF. This project will characterise the movement and functions of this protein with the aim of identifying novel targets for more effective drug therapies.
Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies. Cancer persists as a major cause of morbidity and mortality globally. A major problem is the non-specific action of drugs used for treatment. The minicell is a drug delivery vehicle, capable of packaging a variety of drugs. The project will develop tumour-specific antibodies that will target minicells to tumours, improving cancer survival rates.